Acetylon Pharmaceuticals Highlights Positive Interim Phase 1b Clinical Data Of Ricolinostat (ACY-1215) In Multiple Myeloma At American Society of Hematology Annual Meeting

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA. The two trials are the Phase 1b dose escalation portion of a Phase 1/2 study of ricolinostat in combination with bortezomib (Velcade®) and dexamethasone and a Phase 1b dose escalation study of ricolinostat in combination with lenalidomide (Revlimid®) and dexamethasone, both for the treatment of patients with relapsed or refractory multiple myeloma (MM).

Help employers find you! Check out all the jobs and post your resume.

Back to news